Acrivon Therapeutics (ACRV) to Release Quarterly Earnings on Thursday

Acrivon Therapeutics (NASDAQ:ACRV) is anticipated to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.66) per share for the quarter.

Acrivon Therapeutics Stock Up 1.9 %

Shares of Acrivon Therapeutics stock opened at $5.46 on Thursday. Acrivon Therapeutics has a twelve month low of $4.69 and a twelve month high of $11.90. The business has a 50-day moving average price of $5.56 and a 200 day moving average price of $6.73. The firm has a market cap of $170.00 million, a PE ratio of -2.02 and a beta of 0.85.

Analyst Ratings Changes

Several equities analysts recently weighed in on ACRV shares. KeyCorp started coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating for the company. Cantor Fitzgerald initiated coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating for the company. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Acrivon Therapeutics has a consensus rating of “Buy” and a consensus target price of $23.67.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.